Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features

Accepted/In Press date: 16 September 2022

Published date: 4 November 2022

Additional Information: Funding Information: In the past five years, A.S. has received in-kind contributions from Illumina and Oxford Nanopore Technology and is a shareholder of Illumina. She is a company director and shareholder of SERENOx Ltd. A.S. has received honoraria from Exact Sciences, Janssen, Astra Zeneca, Abbvie and Beigene, non-restricted research grants from Janssen and Astra Zeneca and an educational grant from Abbvie. A.R.P. receives research funding from Celgene/BMS, Gilead, Napp and Roche. N.A. received speaker fees from Gilead. P.A., T.J., U.M., M.R. and D.B. are employees of Illumina, a public company that develops and markets systems for genetic analysis. The remaining authors declare no competing interests. Funding Information: Patient material was obtained from the UK CLL Biobank, University of Liverpool, which is funded by Blood Cancer UK. This work was supported by the Genomics England Research Consortium and the CLL pilot consortium (full list of Individual consortia authors are listed in the ). This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. This work was supported by the National Institute for Health Research Oxford Biomedical Research Centre (A.S., D.V. and K.R.). The views expressed in this publication are those of the authors and not necessarily those of the Department of Health. The work of P.R. was supported by the Japan Society for the Promotion of Science Postdoctoral standard program. The work of R.S.H. is supported Wellcome Trust (214388) and Cancer Research UK (C124388) grants. The work of A.R.P. and S.D. was supported by Blood Cancer UK. A.B. received D.Phil. funding from Health Education England and Genomics England. J.I.M.-S. is funded by the European Research Council under the European Union’s Horizon 2020 research and innovation program (Project BCLLATLAS, grant agreement 810287). J.C.S. is funded by Cancer Research UK (ECRIN-M3 accelerator award C42023/A29370, Southampton Experimental Cancer Medicine Centre grant C24563/A15581, Cancer Research UK Southampton Centre grant C34999/A18087 and program C2750/A23669). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Funding Information: Patient material was obtained from the UK CLL Biobank, University of Liverpool, which is funded by Blood Cancer UK. This work was supported by the Genomics England Research Consortium and the CLL pilot consortium (full list of Individual consortia authors are listed in the Supplementary Material). This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. This work was supported by the National Institute for Health Research Oxford Biomedical Research Centre (A.S., D.V. and K.R.). The views expressed in this publication are those of the authors and not necessarily those of the Department of Health. The work of P.R. was supported by the Japan Society for the Promotion of Science Postdoctoral standard program. The work of R.S.H. is supported Wellcome Trust (214388) and Cancer Research UK (C124388) grants. The work of A.R.P. and S.D. was supported by Blood Cancer UK. A.B. received D.Phil. funding from Health Education England and Genomics England. J.I.M.-S. is funded by the European Research Council under the European Union’s Horizon 2020 research and innovation program (Project BCLLATLAS, grant agreement 810287). J.C.S. is funded by Cancer Research UK (ECRIN-M3 accelerator award C42023/A29370, Southampton Experimental Cancer Medicine Centre grant C24563/A15581, Cancer Research UK Southampton Centre grant C34999/A18087 and program C2750/A23669). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Publisher Copyright: © 2022, The Author(s).

Local EPrints ID: 472511

URI: http://eprints.soton.ac.uk/id/eprint/472511

DOI: doi:10.1038/s41588-022-01211-y

ISSN: 1061-4036

PURE UUID: 51cba57f-f16e-4a08-a918-3721daa4b367

ORCID for Jane Gibson: orcid.org/0000-0002-0973-8285

ORCID for Jonathan Strefford: orcid.org/0000-0002-0972-2881

Date deposited: 07 Dec 2022 17:42

Last modified: 17 Mar 2024 02:59